Abstract

Sickle cell disease (SCD) is one of the most common hemoglobinopathies. Due to its high prevalence, with about 20 million affected individuals worldwide, the development of novel effective treatments is highly warranted. While transplantation of allogeneic hematopoietic stem cells (HSC) is the standard curative treatment approach, a variety of gene transfer and genome editing strategies have demonstrated their potential to provide a prospective cure for SCD patients. Several stratagems employing CRISPR-Cas nucleases or base editors aim at reactivation of γ-globin expression to replace the faulty β-globin chain. The fetal hemoglobin (HbF), consisting of two α-globin and two γ-globin chains, can compensate for defective adult hemoglobin (HbA) and reverse the sickling of hemoglobin-S (HbS). Both disruption of -regulatory elements that are involved in inhibiting γ-globin expression, such as BCL11A or LRF binding sites in the γ-globin gene promoters (), or the lineage-specific disruption of BCL11A to reduce its expression in human erythroblasts, have been demonstrated to reestablish HbF expression. Alternatively, the point mutation in the gene has been corrected using homology-directed repair (HDR)-based methodologies. In general, genome editing has shown promising results not only in preclinical animal models but also in clinical trials, both in terms of efficacy and safety. This review provides a brief update on the recent clinical advances in the genome editing space to offer cure for SCD patients, discusses open questions with regard to off-target effects induced by the employed genome editors, and gives an outlook of forthcoming developments.

MeSH

Anemia, Sickle Cell, Cells, Therapeutics, Globins, Genes, Genome, Hemoglobins, Gene Editing

Cited by

• The Effectiveness of Common Interventions in the Management of Sickle Cell Disease in Primary Care Settings: A Review. Cureus, 2023
• Immune modulation permits tolerance and engraftment in a murine model of late-gestation transplantation. Blood Adv, 2024
• On- and off-target effects of paired CRISPR-Cas nickase in primary human cells. Mol Ther, 2024
• Survey of attitude to human genome modification in Nigeria. J Community Genet, 2023
• Comprehensive analysis of off-target and on-target effects resulting from liver-directed CRISPR-Cas9-mediated gene targeting with AAV vectors. Mol Ther Methods Clin Dev, 2024
• Selecting patients with sickle cell disease for gene addition or gene editing-based therapeutic approaches: Report on behalf of a joint EHA Specialized Working Group and EBMT Hemoglobinopathies Working Party consensus conference. Hemasphere, 2025
• Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target Ther, 2024
• Current and Future Therapeutics for Treating Patients with Sickle Cell Disease. Cells, 2024
• Disrupting ZBTB7A or BCL11A binding sites reactivates fetal hemoglobin in erythroblasts from healthy and β 0-thalassemia/HbE individuals. Sci Rep, 2025